Trial Profile

A Phase 1/2 Open-Label, Randomized, Concurrently-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-102 in Adult PKU Subjects With PAH Deficiency

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 31 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevufenogene nofeparvovec (Primary)
Indications Phenylketonuria
Focus Adverse reactions; First in man; Registrational; Therapeutic Use
Acronyms pheNIX; pheNOIX PKU
Sponsors Homology Medicines

Most Recent Events

24 Aug 2023 Status changed from active, no longer recruiting to discontinued.
28 Feb 2023 Status changed from suspended to active, no longer recruiting.
02 Feb 2023 Planned End Date changed from 1 Sep 2023 to 1 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com